Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02824913 · ClinicalTrials.gov registry record · Phase 2
Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
A Phase 2 study, sponsored by Parion Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02824913 is a Phase 2 study that was terminated before completion, run by Parion Sciences. The registered enrollment target is 1 participants.
The verdict
NCT02824913, a Phase 2 study, was terminated before completion, sponsored by Parion Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this Phase 2a study is to assess changes in tear volume by the non-invasive techniques Ultra High Resolution Optical Coherence Tomography (UHR-OCT) following the administration of P-321 Ophthalmic Solution or Placebo in subjects with tear deficient dry eye disease.
Interventions
- DRUG P-321 Ophthalmic Solution
- DRUG P-321 Ophthalmic Solution placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-07 |
| Est. Completion | 2017-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02824913
The ClinicalTrials.gov registry entry for NCT02824913 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Parion Sciences, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which P-321 Ophthalmic Solution is the first listed.
NCT02824913 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02824913 about?
NCT02824913 is a clinical study titled "Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease". The purpose of this Phase 2a study is to assess changes in tear volume by the non-invasive techniques Ultra High Resolution Optical Coherence Tomography (UHR-OCT) following the administration of P-321 Ophthalmic Solution or Placebo in subjects with tear deficient dry eye disease.
What is the current status of trial NCT02824913?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-07. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02824913?
The interventions under investigation include: P-321 Ophthalmic Solution (DRUG), P-321 Ophthalmic Solution placebo (DRUG).
Who is sponsoring clinical trial NCT02824913?
This trial is sponsored by Parion Sciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.